Bruker Daltonics: leading the way from basic research to mass-spectrometry-based clinical applications.
For several years, Bruker Daltonics has been committed to the development of new applications of mass spectrometry in clinical research, which have the potential to become next-generation diagnostic procedures. After introducing the CLINPROTtrade mark product a couple of years ago, for biofluid analysis in the search of predictive peptide biomarkers indicating certain disease conditions, Bruker Daltonics recently expanded their portfolio with the MALDI BioTypertrade mark and the MALDI Molecular Imagertrade mark to enter new markets, such as the identification of microorganisms and molecular imaging. This article focuses on the current activities and future perspectives of these new clinical research solutions.
Pusch
Wolfgang
W
Bruker Daltonik GmbH, Fahrenheitstrasse 4, 28359 Bremen, Germany. Wolfgang.Pusch@bdal.de
D000818:Animals; D035843:Biomedical Research / Q000379:methods* / Q000639:trends; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods / Q000639:trends; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods / Q000639:trends